Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Sight Sciences reports recurring developments as an eyecare technology company developing and commercializing interventional ophthalmic devices for glaucoma and dry eye disease. Its news commonly covers financial results and guidance, segment trends in Interventional Glaucoma and Interventional Dry Eye, and clinical data for the OMNI Surgical System and TearCare System.
Company updates also address investor conference participation, intellectual property matters involving interventional glaucoma patents, and product positioning across minimally invasive glaucoma surgery and evaporative dry eye treatment. News about SGHT centers on commercialization, reimbursement-sensitive procedure adoption, clinical evidence, and operating performance in its ophthalmic device portfolio.
Sight Sciences (Nasdaq: SGHT) announced a U.S. District Court order (entered March 27, 2026) that preserved a jury verdict finding Alcon willfully infringed three Sight Sciences patents and awarded monetary damages in excess of $34 million.
The order also provides an ongoing royalty of 10% of Hydrus revenue through November 10, 2028. A final judgment will follow after supplemental damages and pre-judgment interest are calculated; the judgment is subject to appeal and USPTO reexamination. The company expects a $5.4 million success fee to operating expenses payable to its counsel.
Sight Sciences (Nasdaq: SGHT) reported Q4 2025 revenue of $20.4M (+7% YoY) and full-year 2025 revenue of $77.4M (‑3% YoY). Gross margin was 87% in Q4 and 86% for FY2025. Adjusted operating expenses fell 13% year-over-year. Cash totaled $92.0M at year-end. The company provided 2026 guidance of $82M–$88M revenue and adjusted operating expenses of $93M–$96M.
Management cited commercial traction in glaucoma and dry eye and a pathway toward cashflow breakeven.
Sight Sciences (Nasdaq: SGHT) will report fourth quarter and full year financial results for the period ended December 31, 2025 after market close on Wednesday, March 4, 2026.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET and a live webcast and archived replay will be available on the company's Investors page. The replay will be accessible for at least 90 days.
Sight Sciences (Nasdaq: SGHT) provided preliminary, unaudited Q4 and full-year 2025 financial highlights for the period ended December 31, 2025. Q4 2025 revenue is expected to be $20.3M–$20.4M (≈+7% at midpoint). Full-year 2025 revenue is expected to be $77.3M–$77.4M (≈-3% at midpoint). Q4 Dry Eye revenue is ~$0.7M (+~130% YoY); full-year Dry Eye revenue is ~$1.6M vs $4.0M in 2024. Cash and cash equivalents were approximately $92M at Dec 31, 2025; cash used in 2025 totaled ~$28M. Results are preliminary and subject to audit with final results expected in March 2026.
Sight Sciences (NASDAQ: SGHT) reported three peer‑reviewed publications (Nov 1–Nov 11, 2025) showing the OMNI surgical system with TruSync technology lowers intraocular pressure (IOP) and medication use in cataract-combination and standalone glaucoma procedures, including analyses in African American patients.
Key results: a 24‑month prospective cohort (n=18) showed mean IOP 26.1 mmHg reduced by 9.7 mmHg at 12 months and 10.6 mmHg at 24 months, medications fell from 1.8 to 0.5 by 24 months, with two‑thirds medication‑free at Month 24. A ~13,000‑eye IRIS registry analysis found the highest ≥20% IOP reduction rate with OMNI among MIGS devices. A 220‑eye subgroup showed IOP reduction up to 3 years regardless of lens status or severity.
Sight Sciences (Nasdaq: SGHT) reported Q3 2025 results and raised full‑year guidance on Nov 6, 2025. Q3 revenue was $19.9M (‑1% YoY) with Surgical Glaucoma revenue of $19.7M (+6% YoY) and Dry Eye revenue of $0.2M (‑88% YoY). Gross profit was $17.2M and gross margin improved to 86%. Q3 adjusted operating expenses fell to $19.8M (‑17% YoY) and GAAP operating expenses were $25.1M, which included $2.8M of restructuring charges.
The company raised 2025 revenue guidance to $76.0M–$78.0M and cut adjusted operating expense guidance to $90M–$92M. Cash was $92.4M and long‑term debt $40.0M as of Sept 30, 2025.
Sight Sciences (Nasdaq: SGHT) announced the appointments of Alison (Ali) Bauerlein as Chief Operating Officer and James (Jim) Rodberg as Chief Financial Officer, effective November 5, 2025.
The company said the new COO role will support scaling reimbursed interventional dry eye and MIGS commercial efforts. Bauerlein joins the executive team after serving as Sight Sciences CFO since April 2023 and previously helped scale Inogen to over $350 million in annual sales. Rodberg was promoted from VP of Finance and corporate controller, has 20 years of finance and accounting experience and served as interim CFO in 2023.
The board also reported that Erica Rogers (six years) and Brenda Becker (three years) have stepped down from the board.
Sight Sciences (Nasdaq: SGHT) will present at two investor conferences in New York in November and December 2025. Management will present at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 8:20 AM PT / 11:20 AM ET and at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 5:30 AM PT / 8:30 AM ET. Interested parties can access a live and archived webcast of each fireside chat via the company’s Investors website at https://investors.sightsciences.com/.
Sight Sciences (Nasdaq: SGHT) will report third quarter 2025 financial results for the period ended September 30, 2025 after market close on Thursday, November 6, 2025.
Management will discuss results on a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Investors can access a live and archived webcast on the company website at www.sightsciences.com under the Investors & News & Events section. The webcast replay will be available for at least 90 days after the event.
Sight Sciences (Nasdaq: SGHT) announced that two Medicare Administrative Contractors, Novitas Solutions and First Coast Service Options, established jurisdiction-wide pricing for CPT 0563T (TearCare procedure) effective for dates of service on or after January 1, 2025.
The two MACs cover an estimated 10.4 million covered lives, representing approximately 30% of Medicare fee-for-service enrollees in their jurisdictions. Claims will be payable based on individual medical necessity determinations and local fee schedules will be published on the MACs' websites.
The company also launched a Sight Access Portal to assist providers with benefit verifications and reimbursement, and said it will provide updated 2025 revenue and adjusted operating expenses guidance during its Q3 2025 earnings call.